CSF2 and familial pancreatic carcinoma: In a clinical trial of patients with refractory pancreatic cancer where GM-CSF was used as an adjuvant during administration of personalized neoantigen peptides (iNeo-Vac-P01), higher IFN-γ blood titer and increased counts of CD4+ and CD8+ effector memory T cells were observed after vaccination (60).